Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs ARGX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARGX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ARGX Overall Winner 6-Pillar Tally: MRNA 3 – 3 ARGX Matrix Metrics: MRNA 4 – 6 ARGX

As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas ARGX carries 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs ARGX
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
ARGX NASDAQ Head-to-Head Winner
argenx SE American Depositary Shares
Biological Products, (No Diagnostic Substances)
$925.70
-1.73% 1D
Market Cap $59.3B
TTM Revenue $5.92B
Forward P/E 27.8x
Beta / 30D Vol 0.56β · 31% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.4 · SMA20: $926.20 · SMA50: $917.81

6-Pillar Scorecard Institutional Category Breakdown (MRNA 3 – 3 ARGX)

Columns: Metric · MRNA · ARGX
1. Valuation Multiples MRNA
Forward P/E 23.0x 27.8x
Trailing P/E 23.0x 32.6x
PEG Ratio N/M 1.28x
EV / Revenue 33.1x 10.0x
2. Growth & Scale ARGX
Revenue Growth (YoY) +29.2% +52.1%
Earnings Growth (YoY) -85.1% +50.6%
TTM Revenue (USD) $2.52B $5.92B
Market Cap $80.7B $59.3B
3. Profitability & Quality ARGX
Gross Margin -42.0% 59.8%
Operating Margin -80.8% 31.9%
Net Profit Margin -110.5% 31.7%
Return on Equity (ROE) -34.5% 23.6%
4. Balance Sheet & Cash Flow ARGX
Cash Generation (TTM) -$2.04B $1.90B EBITDA
Cash Flow Margin -81.0% 32.1% EBITDA Mgn
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $5.38 Book/Sh · 23.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 89.6% (52nd %ile) 32.8% (33rd %ile)
Put/Call OI Skew 1.05x (Balanced) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 27.9% of Rev ($1.65B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (4) vs ARGX (6)
Institutional Metric MRNA ARGX Criterion Row Edge
Market Capitalization
Scale
$80.7B $59.3B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 32.6x Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x 27.8x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% +52.1% Higher Growth ARGX
Operating Margin (TTM)
Profitability
-80.8% 31.9% Higher Margin ARGX
Net Profit Margin
Profitability
-110.5% 31.7% Higher Margin ARGX
Return on Equity (ROE)
Capital Efficiency
-34.5% 23.6% Higher ROE ARGX
52-Week Range Position
Momentum
67% ($22–$281) 64% ($662–$1,073) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 0.56β · 31% Vol Lower Realized Risk ARGX
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 49.6 / 100 (HOLD) Higher Composite ARGX
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $5.92B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 59.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev 1.28x PEG · 10.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $1.90B EBITDA ($5.38 Book/Sh · 23.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARGX +9.47 pp
MRNA: -3.77% · ARGX: +5.7%
3M Horizon MRNA +48.85 pp
MRNA: +40.4% · ARGX: -8.45%
6M Horizon MRNA +301.17 pp
MRNA: +315.96% · ARGX: +14.79%
1Y Horizon MRNA +705.24 pp
MRNA: +706.45% · ARGX: +1.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs ARGX. Trailing 12-month operating profitability (MRNA -80.8% vs ARGX 31.9%) and valuation multiples (MRNA 23.0x vs ARGX 27.8x Forward P/E) are benchmarked directly in Pillar 4 below.

MRNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.52B
Gross Margin-42.0%
Op. Margin-80.8%
ROE / Fwd P/E-34.5% · 23.0x
ARGX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.92B
Gross Margin59.8%
Op. Margin31.9%
ROE / Fwd P/E23.6% · 27.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARGX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.8%
IV Percentile 33rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
ARGX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $59.3B market capitalization and 31.9% operating margin.
OpEx & R&D Reinvestment 27.9% of Rev ($1.65B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs ARGX Key Questions & Quantitative Answers

As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas ARGX carries 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin). Technically, MRNA sits in a Neutral phase (RSI 41.5, CONSOLIDATION options structure) and ARGX sits in a Neutral phase (RSI 50.4, UNCLASSIFIED options structure).

ARGX leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with ARGX at +52.1% YoY revenue growth and +50.6% YoY earnings growth on $5.92B TTM revenue (59.8% gross margin, 31.9% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus $5.92B for ARGX. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 27.9% of Rev ($1.65B) (0 disclosures) for ARGX.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas ARGX trades at 27.8x Forward P/E, 32.6x Trailing P/E, 1.28x PEG, and 10.0x EV/Revenue (32.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus ARGX (23.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, ARGX carries 32.8% implied volatility (33rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.56β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.